Ligand Pharmaceuticals' executives will present at two investor conferences in September 2025, with opportunities for one-on-one meetings.
Quiver AI Summary
Ligand Pharmaceuticals Incorporated announced that its CEO Todd Davis and CFO Tavo Espinoza will participate in two upcoming investor conferences: a fireside chat at the Citi 20th Annual BioPharma Conference in Boston on September 3, 2025, and a presentation at the H.C. Wainwright 27th Annual Global Investment Conference in New York on September 9, 2025. The management team will also host one-on-one meetings with investors at these events. Ligand focuses on supporting the development of high-value biopharmaceuticals through financing and licensing, aiming to create a diverse portfolio of revenues while maintaining low operational costs. The company offers technologies like the Captisol® and NITRICIL™ platforms and partners with major pharmaceutical firms to enhance their late-stage development and commercialization efforts. For more information, interested parties can visit Ligand's website or follow them on social media.
Potential Positives
- Participation in prominent investor conferences showcases Ligand Pharmaceuticals' commitment to engaging with investors and enhancing visibility in the biopharmaceutical sector.
- Opportunity for one-on-one meetings with investors demonstrates Ligand's proactive approach to fostering investor relations and transparency.
- The press release highlights Ligand's partnerships with leading pharmaceutical companies, reinforcing the company's credibility and potential for future growth in the market.
- The mention of their innovative technology platforms, Captisol® and NITRICIL™, emphasizes Ligand’s focus on scientific advancement and diversification in the biopharmaceutical industry.
Potential Negatives
- Participation in multiple investor conferences may indicate the company is seeking to bolster investor confidence amid concerns about its current performance or strategies.
- The emphasis on low corporate cost structure and revenue generation through partnerships suggests potential dependency on external collaborations, which may be seen as a vulnerability.
- Highlighted need for investor engagement through one-on-one meetings may imply challenges in attracting investor interest or confidence independently.
FAQ
When are the upcoming investor conferences for Ligand Pharmaceuticals?
Ligand Pharmaceuticals will participate in the Citi 20th Annual BioPharma Conference on September 3, 2025, and the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025.
Who from Ligand Pharmaceuticals will be participating in the conferences?
CEO Todd Davis and CFO Tavo Espinoza will represent Ligand Pharmaceuticals at the upcoming investor conferences.
How can investors schedule one-on-one meetings with Ligand management?
Investors interested in one-on-one meetings should contact their Citi or H.C. Wainwright representative for arrangements.
What is Ligand Pharmaceuticals' business model?
Ligand's business model focuses on funding mid- to late-stage drug development and licensing technologies to generate diversified revenue streams.
What technologies does Ligand Pharmaceuticals utilize?
Ligand operates Captisol® for drug solubility and stability, and NITRICIL™ for tunable drug dosing and adjustable release profiles.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$LGND Insider Trading Activity
$LGND insiders have traded $LGND stock on the open market 11 times in the past 6 months. Of those trades, 5 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $LGND stock by insiders over the last 6 months:
- TODD C DAVIS (Chief Executive Officer) has made 3 purchases buying 9,510 shares for an estimated $1,000,456 and 0 sales.
- OCTAVIO ESPINOZA (Chief Financial Officer) has made 2 purchases buying 1,500 shares for an estimated $156,090 and 1 sale selling 5,000 shares for an estimated $575,148.
- ANDREW REARDON (CLO & Secretary) has made 0 purchases and 3 sales selling 2,000 shares for an estimated $218,312.
- JOHN W KOZARICH has made 0 purchases and 2 sales selling 1,401 shares for an estimated $178,335.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$LGND Hedge Fund Activity
We have seen 139 institutional investors add shares of $LGND stock to their portfolio, and 131 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 336,462 shares (+608.1%) to their portfolio in Q2 2025, for an estimated $38,249,000
- RANGER INVESTMENT MANAGEMENT, L.P. added 109,935 shares (+57.8%) to their portfolio in Q2 2025, for an estimated $12,497,410
- PRIVATE CAPITAL MANAGEMENT, LLC added 81,128 shares (+54.8%) to their portfolio in Q2 2025, for an estimated $9,222,631
- CASTLEARK MANAGEMENT LLC removed 66,463 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $7,555,513
- PRUDENTIAL FINANCIAL INC removed 62,040 shares (-60.2%) from their portfolio in Q1 2025, for an estimated $6,522,885
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ added 61,951 shares (+22.3%) to their portfolio in Q2 2025, for an estimated $7,042,589
- GAMMA INVESTING LLC removed 61,836 shares (-99.2%) from their portfolio in Q2 2025, for an estimated $7,029,516
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$LGND Analyst Ratings
Wall Street analysts have issued reports on $LGND in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- RBC Capital issued a "Outperform" rating on 08/08/2025
- Oppenheimer issued a "Outperform" rating on 07/30/2025
- Stifel issued a "Buy" rating on 04/10/2025
To track analyst ratings and price targets for $LGND, check out Quiver Quantitative's $LGND forecast page.
$LGND Price Targets
Multiple analysts have issued price targets for $LGND recently. We have seen 3 analysts offer price targets for $LGND in the last 6 months, with a median target of $162.0.
Here are some recent targets:
- Douglas Miehm from RBC Capital set a target price of $185.0 on 08/08/2025
- Trevor Allred from Oppenheimer set a target price of $162.0 on 07/30/2025
- Annabel Samimy from Stifel set a target price of $143.0 on 04/10/2025
Full Release
JUPITER, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences:
-
Citi 20th Annual BioPharma Conference (Boston):
Management will participate in a fireside chat on September 3, 2025 at 11:15 a.m. ET.
-
H.C. Wainwright 27
th
Annual Global Investment Conference (New York)
: Management will present on September 9, 2025 at 1:00 p.m. ET.
Ligand management is scheduled to host one-on-one meetings with investors and attendees during these conferences. Investors interested in arranging one-on-one meetings should contact their Citi or H.C. Wainwright representative.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to attempt to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. We operate two infrastructure-light royalty generating technology IP platform technologies. Our Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Our NITRICIL™ platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications. We have established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter International. For more information, please visit
www.ligand.com
. Follow Ligand on
X
and
LinkedIn
.
We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts.
Contacts
Investors:
Melanie Herman
[email protected]
(858) 550-7761
Media:
Kellie Walsh
[email protected]
(914) 315-6072
